Tobias Janowitz

9.8k total citations · 4 hit papers
53 papers, 3.6k citations indexed

About

Tobias Janowitz is a scholar working on Molecular Biology, Oncology and Physiology. According to data from OpenAlex, Tobias Janowitz has authored 53 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 17 papers in Oncology and 15 papers in Physiology. Recurrent topics in Tobias Janowitz's work include Nutrition and Health in Aging (9 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Pancreatic and Hepatic Oncology Research (6 papers). Tobias Janowitz is often cited by papers focused on Nutrition and Health in Aging (9 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Pancreatic and Hepatic Oncology Research (6 papers). Tobias Janowitz collaborates with scholars based in United States, United Kingdom and Germany. Tobias Janowitz's co-authors include Douglas T. Fearon, Duncan I. Jodrell, Claire M. Connell, Edward W. Roberts, James O. Jones, David A. Tuveson, Matthew Kraman, R. J. Wells, Derek Chan and Qi Zhao and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Tobias Janowitz

50 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer

2013 1.5k citations James O. Jones, Claire M. Connell et al. profile →
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial

2013 405 citations Tobias Janowitz et al. profile →
Enhancing the Efficacy of Glutamine Metabolism Inhibitors in Cancer Therapy

2021 192 citations Wen‐Hsuan Yang, Yijian Qiu et al. Trends in cancer profile →
Why do patients with cancer die?

2024 43 citations Mariam Jamal‐Hanjani, Tobias Janowitz et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tobias Janowitz United States	22	2.0k	1.1k	1.0k	816	574	53	3.6k
Christina L. Roland United States	30	1.7k 0.8×	484 0.4×	945 0.9×	1.4k 1.8×	585 1.0×	126	3.6k
Ronan J. Kelly United States	38	2.5k 1.2×	660 0.6×	1.7k 1.7×	1.8k 2.2×	535 0.9×	158	4.9k
Cindy Neuzillet France	29	2.2k 1.1×	567 0.5×	1.2k 1.2×	657 0.8×	736 1.3×	136	3.5k
Barbara Schmalfeldt Germany	33	1.5k 0.7×	728 0.6×	1.2k 1.2×	386 0.5×	855 1.5×	130	4.2k
Xiaoyun Liao United States	35	4.3k 2.1×	934 0.8×	1.5k 1.5×	1.8k 2.2×	1.1k 1.9×	69	6.2k
Shoji Natsugoe Japan	45	2.5k 1.2×	970 0.8×	2.0k 2.0×	1.4k 1.7×	1.1k 1.9×	198	5.6k
Matthew F. Kalady United States	31	2.7k 1.3×	465 0.4×	1.0k 1.0×	1.2k 1.5×	784 1.4×	105	4.5k
Xishan Hao China	40	1.6k 0.8×	755 0.7×	2.6k 2.6×	1.0k 1.2×	1.6k 2.7×	150	5.1k
Tadaaki Yamada Japan	34	1.9k 0.9×	279 0.2×	1.4k 1.4×	1.7k 2.1×	491 0.9×	212	3.8k
Jun Kinoshita Japan	28	825 0.4×	388 0.3×	730 0.7×	729 0.9×	423 0.7×	159	2.5k

Countries citing papers authored by Tobias Janowitz

Since Specialization

Citations

This map shows the geographic impact of Tobias Janowitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tobias Janowitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tobias Janowitz more than expected).

Fields of papers citing papers by Tobias Janowitz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tobias Janowitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tobias Janowitz. The network helps show where Tobias Janowitz may publish in the future.

Co-authorship network of co-authors of Tobias Janowitz

This figure shows the co-authorship network connecting the top 25 collaborators of Tobias Janowitz. A scholar is included among the top collaborators of Tobias Janowitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tobias Janowitz. Tobias Janowitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Decker-Farrell, Amanda R., et al.. (2025). Cancer therapy and cachexia. Journal of Clinical Investigation. 135(15). 2 indexed citations

Liu, Ying, Ezequiel Dantas, Miriam Ferrer, et al.. (2025). Hepatic gluconeogenesis and PDK3 upregulation drive cancer cachexia in flies and mice. Nature Metabolism. 7(4). 823–841. 6 indexed citations

Feliciano, Elizabeth M. Cespedes, Tobias Janowitz, Marcus D. Goncalves, et al.. (2025). Cancer-Associated Cachexia: Bridging Clinical Findings with Mechanistic Insights in Human Studies. Cancer Discovery. 15(8). 1543–1568. 2 indexed citations

Alexeeff, Stacey, Bette J. Caan, Marcus D. Goncalves, et al.. (2025). Early identification of weight loss trajectories in advanced cancer and associations with survival. JNCI Journal of the National Cancer Institute. 117(8). 1729–1732.

Goncalves, Marcus D., Richard F. Dunne, Wendy Phillips, et al.. (2025). Call to Improve Coding of Cancer-Associated Cachexia. JCO Oncology Practice. 21(7). 926–931. 3 indexed citations

Goncalves, Marcus D. & Tobias Janowitz. (2025). Reply to: Overcoming Barriers to Cancer-Associated Cachexia Diagnosis and Management. JCO Oncology Practice. 21(8). 1213–1214. 1 indexed citations

Sun, Qingtao, Miriam Ferrer, Bruno Gegenhuber, et al.. (2024). Area postrema neurons mediate interleukin-6 function in cancer cachexia. Nature Communications. 15(1). 4682–4682. 22 indexed citations

Langer, Henning T., Shakti Ramsamooj, Ezequiel Dantas, et al.. (2024). Restoring adiponectin via rosiglitazone ameliorates tissue wasting in mice with lung cancer. Acta Physiologica. 240(8). e14167–e14167. 2 indexed citations

Petruzzelli, Michele, Miriam Ferrer, Martijn J. Schuijs, et al.. (2022). Early Neutrophilia Marked by Aerobic Glycolysis Sustains Host Metabolism and Delays Cancer Cachexia. Cancers. 14(4). 963–963. 15 indexed citations

10.

Munir, Hafsa, James O. Jones, Tobias Janowitz, et al.. (2021). Stromal-driven and Amyloid β-dependent induction of neutrophil extracellular traps modulates tumor growth. Nature Communications. 12(1). 683–683. 129 indexed citations

11.

Yang, Wen‐Hsuan, et al.. (2021). Enhancing the Efficacy of Glutamine Metabolism Inhibitors in Cancer Therapy. Trends in cancer. 7(8). 790–804. 192 indexed citations breakdown →

12.

Janowitz, Tobias, David Pattinson, Timothy C. Wang, et al.. (2020). Famotidine use and quantitativesymptom tracking for COVID-19 in nonhospitalizedpatients: A case series. Clinical Cancer Research. 26(18). 1 indexed citations

13.

Williams, Edward H., Thomas R. Flint, Claire M. Connell, et al.. (2020). CamGFR v2: A New Model for Estimating the Glomerular Filtration Rate from Standardized or Non-standardized Creatinine in Patients with Cancer. Clinical Cancer Research. 27(5). 1381–1390. 7 indexed citations

14.

Weber, Andrew, et al.. (2020). Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically ventilated COVID-19 patients: a case series. Molecular Medicine. 26(1). 91–91. 66 indexed citations

15.

Casey, Ruth, Olivier Giger, Ian Seetho, et al.. (2018). Rapid disease progression in a patient with mismatch repair-deficient and cortisol secreting adrenocortical carcinoma treated with pembrolizumab. Seminars in Oncology. 45(3). 151–155. 23 indexed citations

16.

Flint, Thomas R., James O. Jones, Miriam Ferrer, Francesco Colucci, & Tobias Janowitz. (2018). A comparative analysis of immune privilege in pregnancy and cancer in the context of checkpoint blockade immunotherapy. Seminars in Oncology. 45(3). 170–175. 16 indexed citations

17.

Flint, Thomas R., Tobias Janowitz, Claire M. Connell, et al.. (2016). Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity. Cell Metabolism. 24(5). 672–684. 270 indexed citations

18.

Janowitz, Tobias, Sarah J. Welsh, Anne Y. Warren, et al.. (2015). Prostatic relapse of an undifferentiated teratoma 24 years after orchidectomy. BMC Research Notes. 8(1). 524–524. 4 indexed citations

19.

Ellul, Mark, Tobias Janowitz, & N.G. Burnet. (2014). Panhypopituitarism secondary to a solitary hypothalamic metastasis. BMJ Case Reports. 2014. bcr2014204283–bcr2014204283. 2 indexed citations

20.

Ubhi, Baljit K., Jiyang Dong, Tobias Janowitz, et al.. (2012). Targeted metabolomics identifies perturbations in amino acid metabolism that sub-classify patients with COPD. Molecular BioSystems. 8(12). 3125–3133. 90 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact